Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, HER2 ‐negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial
International Journal of Cancer · 2025
DOI: 10.1002/ijc.70037 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Milena Beierlein und 43 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erla…. Hauptthemen laut MEDLINE: Letrozole, Breast Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Deutschland GmbH, Novartis Pharma.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Patients with hormone receptor‐positive (HRpos), HER2‐negative (HER2neg) breast cancer (BC) benefit less from neoadjuvant chemotherapy (NACT) than patients with triple‐negative and HER2‐positive BC. In this retrospective analysis of the phase IV PreFace clinical trial (NCT01908556), where postmenopausal HRpos BC patients ( n = 3297) were treated with 5‐year upfront adjuvant letrozole therapy, we evaluated the prognosis of patients treated with adjuvant versus neoadjuvant chemotherapy in HRpos/HER2neg early‐stage BC. HRpos/HER2neg patients with information on (neo)adjuvant chemotherapy ( n = 2895) were retrospectively selected from all patients enrolled in the PreFace trial. Invasive disease‐free survival (iDFS) and overall survival (OS) were compared between patient groups that were treated with neoadjuvant or adjuvant chemotherapy. Chemotherapy was given to 1051 patients (36.3% of all patients), of which 874 (83.2%) received adjuvant chemotherapy and 177 (16.8%) NACT. Pathologic complete response (pCR) rate in the NACT group was 6.9%. Patients treated with NACT had a worse outcome than those treated with adjuvant chemotherapy (5‐year iDFS rate 81% vs. 88%; 5‐year OS rate 89% vs. 93%). This effect was maintained after adjusting for age, BMI, lymph node status, grading, tumor size, and histology (hazard ratio for iDFS: 1.95 (95%CI: 1.28–2.95); hazard ratio for OS: 2.13 (95%CI: 1.24–3.66)). Further adjustment for taxane‐based regimes did not alter results. In conclusion, in this retrospective analysis of patients with early‐stage HRpos/HER2neg BC, patients with NACT had a more unfavorable prognosis than patients treated adjuvantly, independent of patient and tumor characteristics. Prognosis of neoadjuvant patients might be affected by resistance mechanisms, warranting further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Biostatistics Unit, Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
- Department of Gynecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
- Department of Gynecology, University Hospital Leipzig, Leipzig, Germany.
- Breast Unit, Kliniken Essen-Mitte, Essen, Germany.
- Charité-Universitätsmedizin Berlin, Department of Gynecology with Breast Center, Berlin, Germany.
ORCID-Profile: Lothar Häberle, Paul Gass, Chloë Goossens
Förderung
- Novartis Deutschland GmbH
- Novartis Pharma
Zitieren
APA
Beierlein, M., Häberle, L., Nabieva, N., Maass, N., Aktas, B., Kümmel, S., Thomssen, C., Wolf, C., Kolberg, H. C., Brucker, C., Janni, W., Dall, P., Schneeweiss, A., Marme, F., Sütterlin, M. W., Ruebner, M., Theuser, A. K., Hofmann, N. M., Böhm, S., …, & Fasching, P. A. (2025). Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, HER2 ‐negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial. International Journal of Cancer. https://doi.org/10.1002/ijc.70037
Vancouver
Beierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, et al. Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, HER2 ‐negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial. International Journal of Cancer. 2025. doi:10.1002/ijc.70037
BibTeX
@article{Beierlein2025,
author = {Beierlein, Milena and Häberle, Lothar and Nabieva, Naiba and Maass, Nicolai and Aktas, Bahriye and Kümmel, Sherko and Thomssen, Christoph and Wolf, Christopher and Kolberg, Hans-Christian and Brucker, Cosima and Janni, Wolfgang and Dall, Peter and Schneeweiss, Andreas and Marme, Frederik and Sütterlin, Marc W and Ruebner, Matthias and Theuser, Anna-Katharin and Hofmann, Nadine M and Böhm, Sybille and Almstedt, Katrin and Kellner, Sara and Gass, Paul and Lück, Hans-Joachim and Hein, Alexander and Schmatloch, Sabine and Kalder, Matthias and Uleer, Christoph and Juhasz-Böss, Ingolf and Hanf, Volker and Jackisch, Christian and Müller, Volkmar and Rack, Brigitte and Belleville, Erik and Wallwiener, Diethelm and Rody, Achim and Rauh, Claudia and Bayer, Chistian M and Uhrig, Sabrina and Huebner, Hanna and Goossens, Chloë and Brucker, Sara Y and Hack, Carolin C and Fehm, Tanja N and Fasching, Peter A},
title = {Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, HER2 ‐negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.70037}
}
EUVIMED